Clinical trials: in Moldova
Osteoarthritis, Knee
Study of Intra-articular Allocetra in Knee Osteoarthritis
This is a double blind, randomized,multi-center study to evaluate the safety and efficacy of intra-articular administration of Allocetra compared to placebo in patients with symptomatic knee osteoarthritis.
- Trial name
- NCT06233474
- Testing
- Allocetra
- Where
- 12 sites in Denmark, Israel and 1 more
- Volunteers
- 160 people
- Sponsor
- Enlivex Therapeutics Ltd.
Chronic Hepatitis b
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.
- Trial name
- NCT04980482
- Testing
- AB-729, Peg-IFNα-2a
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Arbutus Biopharma Corporation
Hepatitis B, Chronic
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy
- Trial name
- MARCH (NCT04856085)
- Testing
- VIR-2218, VIR-3434, PEG-IFNα
- Where
- 37 sites in United States, Canada and 10 more
- Volunteers
- 244 people
- Sponsor
- Vir Biotechnology, Inc.
Primary Progressive Multiple Sclerosis
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
This is a phase IIa study with GA Depot in subjects with Primary Progressive MS. GA Depot will be administered intramuscularly (IM), once every four weeks for 148 weeks.
- Trial name
- NCT03362294
- Testing
- GA Depot 40mg once monthly, GA Depot 25mg once monthly
- Where
- 7 sites in Israel, Moldova
- Volunteers
- 30 people
- Sponsor
- Mapi Pharma Ltd.
Chronic HBV Infection
A Long-term Observational Study in Participants Who Have Received PBGENE-HBV
Participants who received at least one dose of PBGENE-HBV will be enrolled in this LTFU study.
- Trial name
- ELIMINATE-B (NCT07254208)
- Testing
- PBGENE-HBV
- Where
- 4 sites in United States, Hong Kong and 2 more
- Volunteers
- 45 people
- Sponsor
- Precision BioSciences, Inc.
Surgical Site Infection, Colon Surgery
D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection
Phase III, Prospective, Multinational, Multicenter, Randomized, Controlled, Two-arm, Double Blind Study to assess Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SoC), compared to a SoC treated…
- Conditions
- Surgical Site Infection, Colon Surgery, Abdominal Surgery, Post-Op Infection
- Trial name
- NCT04233424
- Testing
- D-PLEX, Standard of Care (SoC)
- Where
- 62 sites in United States, Bulgaria and 8 more
- Volunteers
- 977 people
- Sponsor
- PolyPid Ltd.
Ulcerative Colitis
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years.
- Trial name
- NCT03519945
- Testing
- Mirikizumab
- Where
- 352 sites in United States, Argentina and 34 more
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company
Autoimmune Diseases
A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)
This is a phase 1 study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and in participants with autoimmune disease(s).
- Trial name
- NCT05418101
- Testing
- VIS171
- Where
- 10 sites in Bulgaria, Germany and 3 more
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Chronic Hepatitis b
Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
This three-part, Phase 1 protocol will be the first clinical study of AB-101. Parts 1 and 2 will be a Phase 1a SAD/MAD of AB-101 in healthy adult subjects.
- Trial name
- NCT05960240
- Testing
- AB-101, Nucleos(t)ide Analogue
- Where
- 10 sites in Hong Kong, Italy and 5 more
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Ulcerative Colitis
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
The goal of this study is to learn if emvistegrast (formerly GS-1427) is effective in treating participants with moderate to severe ulcerative colitis.
- Trial name
- SWIFT (NCT06290934)
- Testing
- emvistegrast
- Where
- 181 sites in United States, Australia and 20 more
- Volunteers
- 228 people
- Sponsor
- Gilead Sciences
Melanoma
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.
- Trial name
- NCT05907122
- Testing
- ABP 206, FDA-licensed Nivolumab, EU-authorized Nivolumab
- Where
- 76 sites in United States, Argentina and 20 more
- Volunteers
- 256 people
- Sponsor
- Amgen
Chronic Plaque Psoriasis
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic…
- Trial name
- NCT03025542
- Testing
- Bimekizumab
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- UCB Biopharma SRL
Dyslipidemia
ALN-APOC3 in Adult Participants With Dyslipidemia
This study is researching an experimental drug called ALN-APOC3 (called "study drug"). The study is focused on participants who have dyslipidemia (abnormal amounts of fats in the blood, including triglycerides and cholesterol)…
- Trial name
- NCT06784349
- Testing
- ALN-APOC3
- Where
- Moldova
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis).
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
- Trial name
- ASCEND-IBD (NCT07113522)
- Testing
- MT-501, MT-201
- Where
- 66 sites in United States, Canada and 3 more
- Volunteers
- 140 people
- Sponsor
- Mirador Therapeutics, Inc.
Urinary Tract Infection, Acute Pyelonephritis
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication)…
- Trial name
- PIVOT-PO (NCT06059846)
- Testing
- TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion
- Where
- 85 sites in United States, Argentina and 17 more
- Volunteers
- 1,690 people
- Sponsor
- Spero Therapeutics
Von Willebrand Disease
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age
The WIL-33 study aimed to determine the efficacy, pharmacokinetics, immunogenicity and safety of wilate as routine prophylaxis in up to 12 paediatric patients (eight evaluable) with severe von Willebrand Disease VWD (defined as…
- Trial name
- NCT04953884
- Testing
- Wilate
- Where
- 9 sites in United States, Czechia and 5 more
- Volunteers
- 12 people
- Sponsor
- Octapharma
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma
Study of SGR-1505 in Mature B-Cell Neoplasms
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
- Conditions
- Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
- Trial name
- NCT05544019
- Testing
- SGR-1505
- Where
- 36 sites in United States, France and 6 more
- Volunteers
- 98 people
- Sponsor
- Schrödinger, Inc.
Ulcerative Colitis (UC), UC - Ulcerative Colitis
Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the clinical efficacy and safety of OD-07656 in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT06850727
- Testing
- OD-07656, Vedolizumab
- Where
- 32 sites in Australia, Austria and 8 more
- Volunteers
- 57 people
- Sponsor
- Odyssey Therapeutics, Inc.
Hepatitis B, Chronic
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
- Trial name
- NCT05612581
- Testing
- VIR-3434, VIR-2218, TDF
- Where
- 15 sites in France, Hong Kong and 4 more
- Volunteers
- 33 people
- Sponsor
- Vir Biotechnology, Inc.
Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
- Trial name
- NCT07142811
- Testing
- Tobevibart, Elebsiran, Bulevirtide
- Where
- 31 sites in Belgium, Bulgaria and 9 more
- Volunteers
- 100 people
- Sponsor
- Vir Biotechnology, Inc.